Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Boehringer Ingelheim Pharmaceuticals |
---|---|
Information provided by: | Boehringer Ingelheim Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00543803 |
This observational study is supposed to assess (under conditions of clinical practice in daily routine) whether treatment with Viramune (nevirapine) in combination with Truvada (tenofovir and emtricitabine) will durably suppress viral load below the limit of detection or will maintain suppression of viral replication (HIV-RNA below limit of detection) achieved under previous anti-retroviral combination therapy after switch to combination treatment of Viramune (nevirapine) and Truvada (tenofovir and emtricitabine).
Condition |
---|
HIV Infections |
Study Type: | Observational |
Official Title: | Observational Non-Interventional Study Evaluating the Safety and Efficacy of Truvada + Nevirapine |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Germany | |
Boehringer Ingelheim | |
Aachen, Germany | |
Boehringer Ingelheim | |
Berlin, Germany | |
Boehringer Ingelheim | |
Dortmund, Germany | |
Boehringer Ingelheim | |
Duisburg, Germany | |
Boehringer Ingelheim | |
Düsseldorf, Germany | |
Boehringer Ingelheim | |
Frankfurt/Main, Germany | |
Boehringer Ingelheim | |
Frankfurt/Oder, Germany | |
Boehringer Ingelheim | |
Freiburg, Germany | |
Boehringer Ingelheim | |
Hamburg, Germany | |
Boehringer Ingelheim | |
Hannover, Germany | |
Boehringer Ingelheim | |
Karlsruhe, Germany | |
Boehringer Ingelheim | |
Koblenz, Germany | |
Boehringer Ingelheim | |
Köln, Germany | |
Boehringer Ingelheim | |
Leipzig, Germany | |
Boehringer Ingelheim | |
Wuppertal, Germany | |
Boehringer Ingelheim | |
Mainz, Germany | |
Boehringer Ingelheim | |
Mannheim, Germany | |
Boehringer Ingelheim | |
München, Germany | |
Boehringer Ingelheim | |
Münster, Germany | |
Boehringer Ingelheim | |
Nürnberg, Germany | |
Boehringer Ingelheim | |
Oldenburg, Germany | |
Boehringer Ingelheim | |
Osnabrück, Germany | |
Boehringer Ingelheim | |
Potsdam, Germany | |
Boehringer Ingelheim | |
Saarbrücken, Germany | |
Boehringer Ingelheim | |
Stuttgart, Germany | |
Boehringer Ingelheim | |
Troisdorf, Germany | |
Boehringer Ingelheim | |
Wiesbaden, Germany | |
Boehringer Ingelheim | |
Magdeburg, Germany |
Study Chair: | Boehringer Ingelheim | Boehringer Ingelheim Pharmaceuticals |
Responsible Party: | Boehringer Ingelheim ( Boehringer Ingelheim, Study Chair ) |
Study ID Numbers: | 1100.1492 |
Study First Received: | October 8, 2007 |
Last Updated: | December 10, 2008 |
ClinicalTrials.gov Identifier: | NCT00543803 |
Health Authority: | Germany: BfArM-Bundesinstitut fuer Arzneimittel und Medizinprodukte (Federal Authoriteis for Drugs and Medica |
Virus Diseases Nevirapine Sexually Transmitted Diseases, Viral HIV Infections |
Sexually Transmitted Diseases Acquired Immunodeficiency Syndrome Retroviridae Infections Immunologic Deficiency Syndromes |
RNA Virus Infections Slow Virus Diseases Immune System Diseases Lentivirus Infections Infection |